The  China Food and Drug Administration (CFDA), the State Administration of Traditional Chinese Medicine and six other government departments issued on April 14 the Opinions of Improving the Safe Supply of Common Low-cost Drugs.
The Opinions target improving price management and procurement practices, establishing reserves for scarce drugs, and increasing policy support to guarantee the production and supply of common low-cost drugs.